NovaBay Pharmaceuticals (NBY)
Market Price (2/9/2026): $0.773 | Market Cap: $4.5 MilSector: Health Care | Industry: Biotechnology
NovaBay Pharmaceuticals (NBY)
Market Price (2/9/2026): $0.773Market Cap: $4.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 73%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 68% | Weak multi-year price returns2Y Excs Rtn is -120%, 3Y Excs Rtn is -167% | Penny stockMkt Price is 0.8 |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -50% | |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 390% | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -54%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -54% | |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% | High stock price volatilityVol 12M is 243% | |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Diabetes Management. | Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22% | |
| Key risksNBY key risks include [1] its precarious financial health and substantial going concern doubts, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 73%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 68% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 390% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Diabetes Management. |
| Weak multi-year price returns2Y Excs Rtn is -120%, 3Y Excs Rtn is -167% |
| Penny stockMkt Price is 0.8 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -50% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -54%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -54% |
| High stock price volatilityVol 12M is 243% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22% |
| Key risksNBY key risks include [1] its precarious financial health and substantial going concern doubts, Show more. |
Qualitative Assessment
AI Analysis | Feedback
NovaBay Pharmaceuticals (NBY) stock has lost about 35% since 10/31/2025 because of the following key factors:
1. Disappointing Q3 2025 Earnings Performance. NovaBay Pharmaceuticals reported its Q3 2025 earnings on November 7, 2025, with an Earnings Per Share (EPS) of -$0.23, significantly missing analysts' expectations of -$0.08 by 187.50%. This substantial earnings miss likely contributed to negative investor sentiment and put downward pressure on the stock.
2. Significant Share Dilution from At-The-Market (ATM) Offering. On January 20, 2026, NovaBay Pharmaceuticals announced an at-the-market (ATM) equity offering agreement, allowing the company to sell up to $100 million worth of its common stock. This announcement caused the stock to tumble 30% on the day it was released, as such offerings typically lead to dilution of existing shareholders' stakes.
Show more
1. Disappointing Q3 2025 Earnings Performance. NovaBay Pharmaceuticals reported its Q3 2025 earnings on November 7, 2025, with an Earnings Per Share (EPS) of -$0.23, significantly missing analysts' expectations of -$0.08 by 187.50%. This substantial earnings miss likely contributed to negative investor sentiment and put downward pressure on the stock.
2. Significant Share Dilution from At-The-Market (ATM) Offering. On January 20, 2026, NovaBay Pharmaceuticals announced an at-the-market (ATM) equity offering agreement, allowing the company to sell up to $100 million worth of its common stock. This announcement caused the stock to tumble 30% on the day it was released, as such offerings typically lead to dilution of existing shareholders' stakes.
Show more
Stock Movement Drivers
Fundamental Drivers
The -33.9% change in NBY stock from 10/31/2025 to 2/8/2026 was primarily driven by a -31.6% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.15 | 0.76 | -33.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 10 | 5.3% |
| Net Income Margin (%) | 34.0% | 31.5% | -7.4% |
| P/E Multiple | 2.0 | 1.4 | -31.6% |
| Shares Outstanding (Mil) | 6 | 6 | -1.0% |
| Cumulative Contribution | -33.9% |
Market Drivers
10/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| NBY | -33.9% | |
| Market (SPY) | 1.3% | 21.8% |
| Sector (XLV) | 9.3% | 6.4% |
Fundamental Drivers
The 97.9% change in NBY stock from 7/31/2025 to 2/8/2026 was primarily driven by a 147.3% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.38 | 0.76 | 97.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 10 | 5.3% |
| Net Income Margin (%) | 37.4% | 31.5% | -15.9% |
| P/E Multiple | 0.6 | 1.4 | 147.3% |
| Shares Outstanding (Mil) | 5 | 6 | -9.7% |
| Cumulative Contribution | 97.9% |
Market Drivers
7/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| NBY | 97.9% | |
| Market (SPY) | 9.6% | 11.9% |
| Sector (XLV) | 21.5% | 3.1% |
Fundamental Drivers
The 72.8% change in NBY stock from 1/31/2025 to 2/8/2026 was primarily driven by a 390.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.44 | 0.76 | 72.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 10 | 390.3% |
| P/S Multiple | 0.2 | 0.4 | 79.3% |
| Shares Outstanding (Mil) | 1 | 6 | -80.3% |
| Cumulative Contribution | 72.8% |
Market Drivers
1/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| NBY | 72.8% | |
| Market (SPY) | 15.8% | 8.5% |
| Sector (XLV) | 8.8% | 4.4% |
Fundamental Drivers
The -98.7% change in NBY stock from 1/31/2023 to 2/8/2026 was primarily driven by a -99.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312023 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 57.30 | 0.76 | -98.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 10 | -26.1% |
| P/S Multiple | 0.2 | 0.4 | 130.1% |
| Shares Outstanding (Mil) | 0 | 6 | -99.2% |
| Cumulative Contribution | -98.7% |
Market Drivers
1/31/2023 to 2/8/2026| Return | Correlation | |
|---|---|---|
| NBY | -98.7% | |
| Market (SPY) | 76.2% | 6.8% |
| Sector (XLV) | 23.8% | 1.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NBY Return | -46% | -85% | -90% | -92% | 1320% | -87% | -100% |
| Peers Return | -21% | -33% | 105% | 43% | 55% | -20% | 91% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| NBY Win Rate | 25% | 17% | 17% | 25% | 50% | 0% | |
| Peers Win Rate | 33% | 43% | 48% | 50% | 55% | 10% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NBY Max Drawdown | -46% | -90% | -90% | -95% | -21% | -87% | |
| Peers Max Drawdown | -42% | -62% | -50% | -27% | -41% | -25% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TARS, SNOA, OCUL, EYPT, ALDX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/6/2026 (YTD)
How Low Can It Go
| Event | NBY | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.6% | -25.4% |
| % Gain to Breakeven | 24434.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -67.7% | -33.9% |
| % Gain to Breakeven | 209.6% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -94.1% | -19.8% |
| % Gain to Breakeven | 1596.4% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -74.8% | -56.8% |
| % Gain to Breakeven | 297.0% | 131.3% |
| Time to Breakeven | Not Fully Recovered days | 1,480 days |
Compare to TARS, SNOA, OCUL, EYPT, ALDX
In The Past
NovaBay Pharmaceuticals's stock fell -99.6% during the 2022 Inflation Shock from a high on 2/18/2021. A -99.6% loss requires a 24434.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About NovaBay Pharmaceuticals (NBY)
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
AI Analysis | Feedback
The 'Alcon' of specialized lid and lash hygiene products.
AI Analysis | Feedback
- AVENOVA®: A prescription eyelid and lash cleanser containing hypochlorous acid for managing common eye conditions.
- CELOVA™: A topical prescription spray with hypochlorous acid used for the management of various skin conditions.
- NEUTROX®: A prescription wound cleanser containing hypochlorous acid to aid in the healing of chronic and acute wounds.
- NOVAWOUND®: A prescription topical solution with hypochlorous acid designed for cleansing and debriding wounds.
- DermaWound®: A line of over-the-counter hydrogel wound dressings for various types of skin wounds.
AI Analysis | Feedback
NovaBay Pharmaceuticals (NBY) operates a diversified sales model that includes direct-to-consumer sales via e-commerce, sales through online retailers, and direct sales to healthcare professionals. According to their SEC filings, no single customer accounts for 10% or more of their net product revenue, which indicates that they do not have a few dominant "major customer companies" in the traditional B2B sense.
Therefore, NovaBay Pharmaceuticals primarily serves individuals, either directly or through fragmented professional channels. The categories of customers it serves include:
- Individuals seeking ophthalmic hygiene products: Consumers who purchase NovaBay's Avenova brand products (e.g., lid and lash hygiene solutions) for managing conditions like dry eye, blepharitis, or for general eye cleanliness. These purchases are typically made through NovaBay's e-commerce channels, Amazon, or other online pharmacies.
- Individuals seeking dermatological skincare products: Consumers who purchase NovaBay's DERMAdoctor brand products for various skincare concerns such as anti-aging, acne, hyperpigmentation, or sensitive skin. These sales occur primarily through NovaBay's own website, Amazon, and other online beauty retailers.
- Eyecare Professionals: Optometrists, ophthalmologists, and other eyecare specialists who purchase Avenova products directly from NovaBay. These professionals either use the products in their practices, recommend them to patients, or resell them. While these are business-to-business transactions for NovaBay, they typically involve individual practices rather than large corporate entities, and the ultimate beneficiary is an individual patient.
AI Analysis | Feedback
nullAI Analysis | Feedback
David E. Lazar, Chief Executive Officer
Mr. Lazar was appointed CEO and a director of NovaBay Pharmaceuticals, effective August 19, 2025. He is described as a private investor known for aggressive investment strategies, capital restructuring, and reverse merger expertise. His investment in NovaBay is intended to support the company's public listing and fund future strategic transactions.
Tommy Law, Chief Financial Officer
Mr. Law was appointed Chief Financial Officer and Treasurer of NovaBay Pharmaceuticals on August 19, 2025. He previously served as the company's Interim Chief Financial Officer and Treasurer since February 2023, and as Corporate Controller since September 2022. Prior to joining NovaBay in December 2019, Mr. Law was a Senior Accountant at KP LLC from January 2017 to December 2019, and an Accounting Manager at Hitachi Solutions America Ltd. from 2012 to 2015.
Justin Hall, Vice President of Business Development
Mr. Hall transitioned to the role of Vice President of Business Development in August 2025, having previously served as President and Chief Executive Officer and General Counsel for NovaBay. He joined NovaBay in February 2013. Prior to his time at NovaBay, Mr. Hall was Corporate Counsel at Accuray Incorporated from 2006 to 2013. His earlier experience includes serving as a FINRA licensed investment advisor at Sagemark Consulting from 2000 to 2006 and as a stockbroker at First Security Van Kasper from 1998 to 2001.
Audrey Kunin, M.D., Chief Product Officer
Dr. Kunin joined NovaBay in November 2021 as Chief Product Officer following the company's acquisition of DERMAdoctor, LLC, which she co-founded. She is a board-certified dermatologist, author, clinician, and educator.
AI Analysis | Feedback
The key risks to NovaBay Pharmaceuticals (NBY) are predominantly centered on its precarious financial health and the inherent uncertainties of its new strategic direction.
- Financial Instability and Going Concern: NovaBay Pharmaceuticals faces significant financial challenges, marked by substantial operating losses, negative pre-tax profit margins, and poor returns on assets. The company has experienced drastic declines in revenue over the past three and five-year periods, operating at a substantial loss despite a high gross margin. Financial reports reveal a troubling net income trajectory and operational deficits, leading to concerns about future growth prospects and sustainability. There are also explicit mentions of current cash flow challenges and the company having previously considered voluntary liquidation and dissolution.
- Uncertainty of Strategic Direction and Revenue Generation: NovaBay Pharmaceuticals has undergone significant changes in its operations, including the divestiture of its primary eyecare business (Avenova Assets) and its Wound Care segment in early 2025. These divestitures have truncated its business model and revenue streams. Under new leadership, the company is now pursuing a strategic shift, potentially towards a reverse merger or acquisition framework. The success of this new strategic direction and its ability to generate sustainable revenue and improve operational profitability remains highly uncertain, posing a critical risk to its future viability.
- Shareholder Dilution: Recent capital restructuring, including a $6 million securities purchase deal with David Lazar, involves the issuance of convertible preferred stock that grants Lazar over 90% equity control on a fully diluted basis. The conversion of these preferred shares into common stock upon shareholder approval could lead to substantial dilution for existing shareholders, potentially negatively impacting the value of their holdings.
AI Analysis | Feedback
nullAI Analysis | Feedback
NovaBay Pharmaceuticals (NBY) operates in the eyecare, wound care, and skincare markets with its main products and services.
The addressable markets for their key products are as follows:
- Avenova (Eyecare - Dry Eye Syndrome Treatment): The U.S. dry eye syndrome treatment market is projected to grow to $4.86 billion by 2030, from $3.02 billion in 2023.
- Avenova (Eyecare - Over-the-Counter Artificial Tears): The global market for over-the-counter artificial tear products is expected to reach nearly $6.4 billion by 2028.
- NeutroPhase / PhaseOne (Wound Care): null
- CelleRx Clinical Reset (Beauty/Dermatology): null
- DERMAdoctor (Skincare): null
AI Analysis | Feedback
NovaBay Pharmaceuticals (NBY) is undergoing significant strategic shifts, having divested its primary revenue-generating assets in early 2025. Future revenue growth is anticipated to be driven by new strategic directions rather than the continuation of previous product lines. The expected drivers of future revenue growth for NovaBay Pharmaceuticals over the next 2-3 years include:- Successful identification and integration of new strategic business combinations or acquisitions. The company's board is actively exploring strategic alternatives, including potential business combinations, which, if successful, could introduce new revenue streams and operational focuses for NovaBay.
- Introduction of novel pharmaceutical products resulting from new research and development (R&D) investments. Following a recent securities purchase deal and the appointment of a new CEO, there is an expectation that a significant cash infusion will support and boost R&D efforts, potentially leading to the development and market launch of new products.
- Expansion into new markets and implementation of innovative growth strategies under new leadership. The new Chief Executive Officer is tasked with steering NovaBay Pharmaceuticals towards innovative growth strategies and aiming for market expansion, which could open up new customer bases and revenue opportunities.
AI Analysis | Feedback
Share Issuance
- In 2025, NovaBay Pharmaceuticals issued pre-funded warrants to purchase an aggregate of 5,405,406 shares of common stock, generating approximately $6.0 million in net proceeds.
- The company also issued 268,750 shares of Series E non-voting convertible preferred stock in 2025, resulting in approximately $2.15 million in net proceeds.
- NovaBay issued 481,250 shares of Series D Preferred Stock to private investor David E. Lazar, yielding gross proceeds of $3.85 million in 2025.
- In 2024, NovaBay Pharmaceuticals implemented a 1-for-35 reverse stock split of its common stock.
Inbound Investments
- In 2025, NovaBay secured a $6 million securities purchase agreement with private investor David E. Lazar for non-voting convertible preferred stock, with an initial $3.85 million received.
- This investment was crucial for NovaBay to regain compliance with NYSE American's continued listing standards, which required a minimum of $6 million in stockholders' equity.
- The proceeds from Lazar's investment are intended to support the company's public listing and fund future strategic investments and/or acquisitions, moving away from a previously considered plan of dissolution.
Outbound Investments
- On January 17, 2025, NovaBay Pharmaceuticals sold its Avenova assets to PRN Physician Recommended Nutriceuticals, LLC for $11.5 million, which constituted the disposal of substantially all of its revenue-generating operations.
- The company divested its PhaseOne® and NeutroPhase® U.S. wound care trademarks to PhaseOne Health LLC for $500,000 on January 8, 2025.
- NovaBay completed the sale of its former wholly-owned subsidiary, DERMAdoctor, Inc., to New Age Investments LLC on March 26, 2025.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.35 |
| Mkt Cap | 0.6 |
| Rev LTM | 30 |
| Op Inc LTM | -66 |
| FCF LTM | -51 |
| FCF 3Y Avg | -62 |
| CFO LTM | -47 |
| CFO 3Y Avg | -59 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 25.0% |
| Rev Chg 3Y Avg | 11.2% |
| Rev Chg Q | 17.1% |
| QoQ Delta Rev Chg LTM | 5.3% |
| Op Mgn LTM | -49.7% |
| Op Mgn 3Y Avg | -308.0% |
| QoQ Delta Op Mgn LTM | 5.9% |
| CFO/Rev LTM | -53.6% |
| CFO/Rev 3Y Avg | -237.2% |
| FCF/Rev LTM | -53.6% |
| FCF/Rev 3Y Avg | -247.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.6 |
| P/S | 7.5 |
| P/EBIT | -6.3 |
| P/E | -6.1 |
| P/CFO | -6.4 |
| Total Yield | -13.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -14.7% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -17.5% |
| 3M Rtn | -10.4% |
| 6M Rtn | 17.6% |
| 12M Rtn | 21.5% |
| 3Y Rtn | 59.2% |
| 1M Excs Rtn | -20.2% |
| 3M Excs Rtn | -12.3% |
| 6M Excs Rtn | 10.2% |
| 12M Excs Rtn | -0.7% |
| 3Y Excs Rtn | -4.4% |
Price Behavior
Price Behavior
| Market Price | $0.76 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/26/2007 | |
| Distance from 52W High | -96.0% | |
| 50 Days | 200 Days | |
| DMA Price | $4.78 | $1.80 |
| DMA Trend | up | up |
| Distance from DMA | -84.1% | -57.8% |
| 3M | 1YR | |
| Volatility | 372.3% | 244.1% |
| Downside Capture | 469.41 | 83.96 |
| Upside Capture | 226.11 | 129.22 |
| Correlation (SPY) | 23.7% | 8.7% |
NBY Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 17.76 | 12.53 | 5.78 | 2.79 | 0.90 | 0.66 |
| Up Beta | 32.42 | 27.83 | 8.62 | 4.20 | 0.28 | 0.22 |
| Down Beta | 27.55 | 21.95 | 12.66 | 5.31 | 1.90 | 1.84 |
| Up Capture | -613% | 579% | 300% | 447% | 184% | -5% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 7 | 22 | 32 | 66 | 120 | 330 |
| Down Capture | 1422% | -102% | -26% | -222% | -12% | 98% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 19 | 28 | 57 | 123 | 405 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NBY | |
|---|---|---|---|---|
| NBY | 71.3% | 242.8% | 1.26 | - |
| Sector ETF (XLV) | 7.7% | 17.3% | 0.27 | 4.3% |
| Equity (SPY) | 15.4% | 19.4% | 0.61 | 8.5% |
| Gold (GLD) | 73.9% | 24.8% | 2.19 | -3.1% |
| Commodities (DBC) | 8.9% | 16.6% | 0.34 | 1.2% |
| Real Estate (VNQ) | 4.6% | 16.5% | 0.10 | 7.0% |
| Bitcoin (BTCUSD) | -27.1% | 44.7% | -0.57 | 14.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NBY | |
|---|---|---|---|---|
| NBY | -74.8% | 141.3% | -0.33 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 2.9% |
| Equity (SPY) | 14.4% | 17.0% | 0.68 | 8.1% |
| Gold (GLD) | 21.4% | 16.9% | 1.03 | 1.5% |
| Commodities (DBC) | 11.5% | 18.9% | 0.49 | 3.1% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 2.8% |
| Bitcoin (BTCUSD) | 16.1% | 58.0% | 0.49 | 9.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NBY | |
|---|---|---|---|---|
| NBY | -54.7% | 332.8% | 0.27 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.54 | 0.6% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 3.8% |
| Gold (GLD) | 15.7% | 15.5% | 0.84 | -2.5% |
| Commodities (DBC) | 8.0% | 17.6% | 0.37 | 2.6% |
| Real Estate (VNQ) | 6.0% | 20.7% | 0.25 | 0.4% |
| Bitcoin (BTCUSD) | 68.7% | 66.7% | 1.08 | 5.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/11/2024 | 5.2% | -2.8% | -82.1% |
| 3/14/2024 | -4.9% | -1.1% | -36.2% |
| 7/21/2020 | -23.0% | -28.6% | -34.2% |
| SUMMARY STATS | |||
| # Positive | 1 | 0 | 0 |
| # Negative | 2 | 3 | 3 |
| Median Positive | 5.2% | ||
| Median Negative | -13.9% | -2.8% | -36.2% |
| Max Positive | 5.2% | ||
| Max Negative | -23.0% | -28.6% | -82.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/02/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/26/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/29/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Poplar, Point Capital Partners Lp | Direct | Buy | 4142025 | 0.58 | 917 | 532 | 575,642 | Form | |
| 2 | Poplar, Point Capital Partners Lp | Direct | Buy | 4142025 | 0.56 | 22,976 | 12,929 | 571,400 | Form | |
| 3 | Poplar, Point Capital Partners Lp | Direct | Buy | 4142025 | 0.52 | 4,538 | 2,367 | 532,032 | Form | |
| 4 | Poplar, Point Capital Partners Lp | Direct | Buy | 4142025 | 0.47 | 300 | 140 | 474,440 | Form | |
| 5 | Poplar, Point Capital Partners Lp | Direct | Buy | 4142025 | 0.61 | 13,292 | 8,095 | 536,831 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.